Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 66

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 66
---
 exercise
such right to require such exercise by the holders thereof in consideration for their investment in the Series C PIPE Financing.

The Preferred Warrants prohibited
us from entering into specified fundamental transactions unless the Successor assumes all of our obligations under the Preferred Warrants
under a written agreement before the transaction is completed. Upon specified corporate events, a holder of the Preferred Warrants thereafter
had the right to receive upon an exercise such shares, securities, cash, assets or any other property whatsoever which the holder would
have been entitled to receive upon the happening of the applicable corporate event had the Preferred Warrant been exercised immediately
prior to the applicable corporate event.

During the three and nine
months ended September 30, 2024, 38 Series A Preferred Warrants were exercised into 38 shares of Series A Preferred Stock for gross proceeds
of $38,000.

During the nine months ended
September 30, 2025, the 625 remaining Series A Preferred Warrants were exercised into 625 shares of Series A Preferred Stock for gross
proceeds of $500,000.

The Company’s Preferred
Warrants were exercisable into Series A Preferred Stock, which had no cash redemption features that required liability treatment. The
Company recorded the Preferred Warrants as equity.

February 2025 Pre-funded Warrants and February 2025 Common Warrants

On February 5, 2025, in connection
with the February 2025 Offering (See Note 8), the Company sold (i) 15,000 shares of Common Stock, (ii) Pre-Funded Warrants to purchase
up to 112,551 shares of Common Stock, and (iii) Common Warrants to purchase up to 127,551 shares of common stock, at a combined public
offering price of $39.20 per share and Warrant. During the three months ended March 31, 2025, 91,214 shares of its common stock were issued
following the exercise of certain Pre-Funded Warrants. During the three months ended June 30, 2025, 10,550 shares of its common stock
were issued following the exercise of certain Pre-Funded Warrants. At September 30, 2025, the remaining 10,787 Pre-Funded Warrants remain
exercisable. The Pre-Funded Warrants are exercisable at any time and have no expiration date

Additionally, in connection
with the February 2025 Offering, the Company issued the February